Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
0.12% $75.49
/ 15 aug 2022 @ 16:00
RATING 2022-09-07 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -13.55 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -13.55 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 75.30 - 76.73 ( +/- 0.94%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-08-17 | Nicholson Garry A | Sell | 23 400 | Stock Option (right to buy) |
2022-08-17 | Nicholson Garry A | Sell | 8 500 | Stock Option (right to buy) |
2022-08-17 | Nicholson Garry A | Sell | 8 500 | Stock Option (right to buy) |
2022-08-17 | Machado Patrick | Sell | 30 000 | Stock Option (right to buy) |
2022-08-17 | George Simeon | Sell | 8 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
-90.54 |
Last 94 transactions |
Buy: 1 295 935 | Sell: 2 703 326 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $75.49 (0.12% ) |
Volume | 1.032 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.